๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

18 recruiting trials

for SSTR Positive Tumors

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression NCT05749289Phase 2, Phase 31 site๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Al18F-octreotide Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ San Diego RayzeBio, Inc. ยท Tests: RYZ101, Standard of Care Endocrine Therapy Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors NCT04665739Phase 229 sites๐Ÿ“ Birmingham๐Ÿ“ Beverly Hills๐Ÿ“ Loma Linda National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms NCT06398444Phase 2, Phase 31 site๐Ÿ“ Shanghai Sinotau Pharmaceutical Group ยท Tests: Lutetium[177Lu] Oxodotreotide Injection Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors NCT06441331Phase 17 sites๐Ÿ“ San Francisco๐Ÿ“ Cincinnati๐Ÿ“ Philadelphia ITM Solucin GmbH ยท Tests: Lutetium Lu 177-Edotreotide, Amino Acid Solution An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. NCT05884255Phase 32 sites๐Ÿ“ Shanghai๐Ÿ“ Tianjin Jiangsu HengRui Medicine Co., Ltd. ยท Tests: Lutetium (177Lu) Oxodotreotide Injection๏ผ›long-acting Octreotide, long-acting Octreotide A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors NCT06632860EARLY Phase 11 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: 68Ga-TATE-RGD, 18-FDG 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. NCT04081701Phase 41 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Ga68-DOTATATE-PET/MRI [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers NCT06479811Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy NCT06427798Phase 1, Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department NCT04104529NA4 sites๐Ÿ“ Bordeaux๐Ÿ“ Marseille๐Ÿ“ Montpellier Institut du Cancer de Montpellier - Val d'Aurelle ยท Tests: Biological collection, tumor collection Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors NCT05687123Phase 110 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Orange National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Toโ€ฆ Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors NCT05636618Phase 1, Phase 220 sites๐Ÿ“ Jacksonville๐Ÿ“ Miami๐Ÿ“ Orlando Perspective Therapeutics ยท Tests: [203Pb]VMT-ฮฑ-NET, [212Pb]VMT-ฮฑ-NET Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. NCT05918302Phase 327 sites๐Ÿ“ Edegem๐Ÿ“ Brussels๐Ÿ“ Liรจge Grupo Espanol de Tumores Neuroendocrinos ยท Tests: 177Lu-edotreotide, Everolimus Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET NCT06784752Phase 367 sites๐Ÿ“ Scottsdale๐Ÿ“ Fayetteville๐Ÿ“ Denver Novartis Pharmaceuticals ยท Tests: [177Lu]Lu-DOTA-TATE, Octreotide LAR Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282n/a20 sites๐Ÿ“ Santiago de Compostela๐Ÿ“ Granada๐Ÿ“ Palma de Mallorca Sociedad Espaรฑola de Medicina Nuclear e Imagen Molecular ยท Tests: Lutetium [177Lu] oxodotreotide/dotatate, Lutetium [177Lu] oxodotreotide/dotatate 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors NCT04888481Phase 21 site๐Ÿ“ Edmonton University of Alberta ยท Tests: 68Ga-HA-DOTATATE "Receptor Radionuclide Therapy With 177Lu-DOTATOC NCT06045260Phase 22 sites๐Ÿ“ Cesena๐Ÿ“ Meldola Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRโ€ฆ ยท Tests: 177Lu-DOTATOC
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy